# SecondWave Systems, Inc.

> SecondWave Systems is a Minneapolis medical device company pioneering bio-ultrasonic medicine: a noninvasive, wearable ultrasound platform that targets the spleen with low-intensity focused ultrasound to calm chronic inflammation - offering patients with conditions like rheumatoid arthritis a drug-free alternative to biologics. Founded in 2019 by Anuj Bhardwaj, Hubert Lim, and Jeff Heyman, it builds on ultrasound expertise from the family-founded Ultran Group and over $15M in non-dilutive government support from DARPA, NIH, and ARPA-H.

- **Founded:** 2019
- **Headquarters:** Minneapolis, United States
- **Founders:** Anuj Bhardwaj (Co-Founder & CEO), Hubert H. Lim (Co-Founder & Chief Scientific Officer), Jeff Heyman (Co-Founder & Chief Operating Officer)
- **Team size:** ~19 employees
- **Products:** SecondWave MINI, Bio-ultrasonic neuromodulation platform, Home-use self-administration system
- **Notable:** Closed $7M Series A in April 2025 to accelerate clinical development., Clinical study showed 10 of 13 rheumatoid arthritis participants improved with splenic ultrasound therapy., Secured over $15M in non-dilutive government funding from DARPA, NIH, ARPA-H, and JPEO-CBRND.

## Products & services

- **SecondWave MINI** — A noninvasive, wearable ultrasound device that delivers low-intensity focused ultrasound to the spleen to reduce acute and chronic inflammation.
- **Bio-ultrasonic neuromodulation platform** — A scalable platform applying low-intensity focused ultrasound to modulate nerves, cells, and organs for conditions including rheumatoid arthritis, long COVID, pain, and hearing disorders.
- **Home-use self-administration system** — A next-generation, intelligence-enabled version designed for patient self-administration at home.

## Achievements

- Closed $7M Series A in April 2025 to accelerate clinical development.
- Clinical study showed 10 of 13 rheumatoid arthritis participants improved with splenic ultrasound therapy.
- Secured over $15M in non-dilutive government funding from DARPA, NIH, ARPA-H, and JPEO-CBRND.
- Achieved FDA 'non-significant risk' designation in early 2021.
- Treated over 100 patients across studies.
- Selected for J&J JLABS and Fogarty Innovation accelerator programs.

## Latest updates

- **2025-04** — Raised $7M Series A led by Treo Ventures and a healthcare strategic to accelerate clinical development.
- **2024-05** — Reported reduction in disease activity in a clinical study of its ultrasound-based anti-inflammatory therapy in rheumatoid arthritis.
- **2025-04** — Began clinical testing of a next-generation home-use, self-administration version of the device.

## Links

- Website: https://secondwaveus.com
- LinkedIn: http://www.linkedin.com/company/secondwave-systems-inc
- Twitter/X: https://twitter.com/secondwavesysus

---

Profile page: https://yespress.io/secondwave-systems-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-08